Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance

Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect. It is widely studied that epigenetic regulation has played important role in the development of tamox...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in genetics Jg. 13; S. 992444
Hauptverfasser: Zhang, Xiulei, Zhang, Qian, Liu, Guangzhi
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Frontiers Media S.A 20.09.2022
Schlagworte:
ISSN:1664-8021, 1664-8021
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect. It is widely studied that epigenetic regulation has played important role in the development of tamoxifen resistance. FOXA1 is a pioneer transcription factor that can translate epigenetic signature into transcription regulation and also drive genome-wide enhancer reprogramming in breast cancer. However, the chromatin super enhancer landscape orchestrated by FOXA1 and the key downstream targets of the FOXA1 oncogenic network in tamoxifen resistance remain elusive. Through analyzing the FOXA1 ChIP-seq data in tamoxifen sensitive MCF7 and tamoxifen resistant MCF7/TamR cells, we show that the FOXA1 chromatin occupancy is enhanced in both the promoter and enhancer regions, and the recruitment events may be E2 dependent in both MCF7 and MCF7/TamR cells. By integratively analyzing the FOXA1 ChIP-seq data and RNA-seq data of MCF7 and MCF7/TamR cells, we find that the enhanced or reduced FOXA1 chromatin binding densities may synchronize the transcriptional activity in tamoxifen resistance. Besides, we identify 1003 super enhancer associated protein coding genes and five super enhancer associated lncRNAs (ATP1A1−AS1, CASC11, CASC15, KCTD21−AS1, LINC00885) in tamoxifen resistance. By KM survival analysis, we find that high expression level of ATP1A1−AS1 and its sense transcript ATP1A1 indicates favorable clinical outcome among the luminal endocrine treated breast cancer patients. Further coexpression analysis indicates that ATP1A1-AS1 is significantly correlated with ATP1A1, and RT-qPCR results show that they both are downregulated in MCF7/TamR cells. Our study shows that the FOXA1 transcriptional regulatory network may promote the development of tamoxifen resistance, and identifies one super enhancer associated lncRNA ATP1A1-AS1 that may work as promising biomarker or drug target in tamoxifen resistance.
AbstractList Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect. It is widely studied that epigenetic regulation has played important role in the development of tamoxifen resistance. FOXA1 is a pioneer transcription factor that can translate epigenetic signature into transcription regulation and also drive genome-wide enhancer reprogramming in breast cancer. However, the chromatin super enhancer landscape orchestrated by FOXA1 and the key downstream targets of the FOXA1 oncogenic network in tamoxifen resistance remain elusive. Through analyzing the FOXA1 ChIP-seq data in tamoxifen sensitive MCF7 and tamoxifen resistant MCF7/TamR cells, we show that the FOXA1 chromatin occupancy is enhanced in both the promoter and enhancer regions, and the recruitment events may be E2 dependent in both MCF7 and MCF7/TamR cells. By integratively analyzing the FOXA1 ChIP-seq data and RNA-seq data of MCF7 and MCF7/TamR cells, we find that the enhanced or reduced FOXA1 chromatin binding densities may synchronize the transcriptional activity in tamoxifen resistance. Besides, we identify 1003 super enhancer associated protein coding genes and five super enhancer associated lncRNAs (ATP1A1−AS1, CASC11, CASC15, KCTD21−AS1, LINC00885) in tamoxifen resistance. By KM survival analysis, we find that high expression level of ATP1A1−AS1 and its sense transcript ATP1A1 indicates favorable clinical outcome among the luminal endocrine treated breast cancer patients. Further coexpression analysis indicates that ATP1A1-AS1 is significantly correlated with ATP1A1, and RT-qPCR results show that they both are downregulated in MCF7/TamR cells. Our study shows that the FOXA1 transcriptional regulatory network may promote the development of tamoxifen resistance, and identifies one super enhancer associated lncRNA ATP1A1-AS1 that may work as promising biomarker or drug target in tamoxifen resistance.
Breast cancer is the leading cause of death in female cancers, and what's worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect. It is widely studied that epigenetic regulation has played important role in the development of tamoxifen resistance. FOXA1 is a pioneer transcription factor that can translate epigenetic signature into transcription regulation and also drive genome-wide enhancer reprogramming in breast cancer. However, the chromatin super enhancer landscape orchestrated by FOXA1 and the key downstream targets of the FOXA1 oncogenic network in tamoxifen resistance remain elusive. Through analyzing the FOXA1 ChIP-seq data in tamoxifen sensitive MCF7 and tamoxifen resistant MCF7/TamR cells, we show that the FOXA1 chromatin occupancy is enhanced in both the promoter and enhancer regions, and the recruitment events may be E2 dependent in both MCF7 and MCF7/TamR cells. By integratively analyzing the FOXA1 ChIP-seq data and RNA-seq data of MCF7 and MCF7/TamR cells, we find that the enhanced or reduced FOXA1 chromatin binding densities may synchronize the transcriptional activity in tamoxifen resistance. Besides, we identify 1003 super enhancer associated protein coding genes and five super enhancer associated lncRNAs (ATP1A1-AS1, CASC11, CASC15, KCTD21-AS1, LINC00885) in tamoxifen resistance. By KM survival analysis, we find that high expression level of ATP1A1-AS1 and its sense transcript ATP1A1 indicates favorable clinical outcome among the luminal endocrine treated breast cancer patients. Further coexpression analysis indicates that ATP1A1-AS1 is significantly correlated with ATP1A1, and RT-qPCR results show that they both are downregulated in MCF7/TamR cells. Our study shows that the FOXA1 transcriptional regulatory network may promote the development of tamoxifen resistance, and identifies one super enhancer associated lncRNA ATP1A1-AS1 that may work as promising biomarker or drug target in tamoxifen resistance.Breast cancer is the leading cause of death in female cancers, and what's worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect. It is widely studied that epigenetic regulation has played important role in the development of tamoxifen resistance. FOXA1 is a pioneer transcription factor that can translate epigenetic signature into transcription regulation and also drive genome-wide enhancer reprogramming in breast cancer. However, the chromatin super enhancer landscape orchestrated by FOXA1 and the key downstream targets of the FOXA1 oncogenic network in tamoxifen resistance remain elusive. Through analyzing the FOXA1 ChIP-seq data in tamoxifen sensitive MCF7 and tamoxifen resistant MCF7/TamR cells, we show that the FOXA1 chromatin occupancy is enhanced in both the promoter and enhancer regions, and the recruitment events may be E2 dependent in both MCF7 and MCF7/TamR cells. By integratively analyzing the FOXA1 ChIP-seq data and RNA-seq data of MCF7 and MCF7/TamR cells, we find that the enhanced or reduced FOXA1 chromatin binding densities may synchronize the transcriptional activity in tamoxifen resistance. Besides, we identify 1003 super enhancer associated protein coding genes and five super enhancer associated lncRNAs (ATP1A1-AS1, CASC11, CASC15, KCTD21-AS1, LINC00885) in tamoxifen resistance. By KM survival analysis, we find that high expression level of ATP1A1-AS1 and its sense transcript ATP1A1 indicates favorable clinical outcome among the luminal endocrine treated breast cancer patients. Further coexpression analysis indicates that ATP1A1-AS1 is significantly correlated with ATP1A1, and RT-qPCR results show that they both are downregulated in MCF7/TamR cells. Our study shows that the FOXA1 transcriptional regulatory network may promote the development of tamoxifen resistance, and identifies one super enhancer associated lncRNA ATP1A1-AS1 that may work as promising biomarker or drug target in tamoxifen resistance.
Author Liu, Guangzhi
Zhang, Qian
Zhang, Xiulei
AuthorAffiliation 2 Henan Provincial Key Medical Laboratory of Genetics , Henan Provincial People’s Hospital , Zhengzhou University , Zhengzhou , China
1 Department of Microbiome Laboratory , Henan Provincial People’s Hospital , Zhengzhou University , Zhengzhou , China
AuthorAffiliation_xml – name: 2 Henan Provincial Key Medical Laboratory of Genetics , Henan Provincial People’s Hospital , Zhengzhou University , Zhengzhou , China
– name: 1 Department of Microbiome Laboratory , Henan Provincial People’s Hospital , Zhengzhou University , Zhengzhou , China
Author_xml – sequence: 1
  givenname: Xiulei
  surname: Zhang
  fullname: Zhang, Xiulei
– sequence: 2
  givenname: Qian
  surname: Zhang
  fullname: Zhang, Qian
– sequence: 3
  givenname: Guangzhi
  surname: Liu
  fullname: Liu, Guangzhi
BookMark eNp9ks1uEzEUhUeoSJTSB2DnJZsJ_hvPeIMUVbRUiloJgcTOcuzrxGXGDraHkkfgrXGaqqIs8MZX9jnfvbLP6-YkxABN85bgBWODfO82EGBBMaULKSnn_EVzSoTg7YApOfmrftWc53yH6-KSMcZPm99XEOIE7b23gHTQ4z77jKJDZQvo8vbbkqCSdMgm-V3xsQpQgs086hLTHgUo9zF9R9UcinceMsrzDhKCsNXB1ELnHI3XBSxaBfP5ZpmRD6joKf7yDkKF1X7loH3TvHR6zHD-uJ81Xy8_frn41K5ur64vlqvWcE5L6zozUEucpRas643kct0Na0F478AIjntiO9f1PddOSA7Aqeux7Jg0ZLDg2FlzfeTaqO_ULvlJp72K2quHg5g2SqfizQiKMCGk4MQyQbnrpDbQWUZlTyXVVprK-nBk7eb1BNbUV0h6fAZ9fhP8Vm3iT1XnwVzQCnj3CEjxxwy5qMlnA-OoA8Q5K9pTRjrRcVyl5Cg1KeacwD21IVgdYqAeYqAOMVDHGFRP_4_H-KIP_1in8eN_nH8Azny-2A
CitedBy_id crossref_primary_10_1186_s12964_024_01599_6
crossref_primary_10_1007_s10495_023_01831_7
crossref_primary_10_1111_jcmm_70296
crossref_primary_10_3390_ijms25063103
crossref_primary_10_3390_ijms24108733
Cites_doi 10.2196/27633
10.1016/s0140-6736(12)61963-1
10.1155/2020/9031723
10.1038/nprot.2013.150
10.1016/j.cell.2013.03.035
10.3892/or.2022.8341
10.1016/S0140-6736(05)66544-0
10.1080/15476286.2020.1712895
10.1016/j.cell.2016.02.067
10.1016/j.ccell.2016.03.010
10.14806/ej.17.1.200
10.2147/OTT.S321669
10.1038/nmeth.3317
10.1093/nar/gkw257
10.1371/journal.pone.0132285
10.1093/bioinformatics/btu638
10.1093/bioinformatics/btp352
10.1089/omi.2011.0118
10.1016/j.cell.2013.09.053
10.1073/pnas.1911584116
10.1186/1471-2407-13-174
10.1038/s41467-021-22024-3
10.3389/fphar.2020.592912
10.1093/jmcb/mjab018
10.1016/j.celrep.2019.09.032
10.1038/ng.730
10.1186/s13059-014-0550-8
10.1093/bioinformatics/btv145
10.1186/gb-2008-9-9-r137
10.3727/096504016x14549667334007
10.3322/caac.21660
10.1038/nmeth.1923
10.1134/s0006297918050139
ContentType Journal Article
Copyright Copyright © 2022 Zhang, Zhang and Liu.
Copyright © 2022 Zhang, Zhang and Liu. 2022 Zhang, Zhang and Liu
Copyright_xml – notice: Copyright © 2022 Zhang, Zhang and Liu.
– notice: Copyright © 2022 Zhang, Zhang and Liu. 2022 Zhang, Zhang and Liu
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fgene.2022.992444
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Zhang et al
EISSN 1664-8021
ExternalDocumentID oai_doaj_org_article_13669641d3624f59ace5d3297292ad9c
PMC9530462
10_3389_fgene_2022_992444
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFS
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-f5c82d1fd2dedf7c949b58b6147fec64071d5f5774af694ee42f709539c18def3
IEDL.DBID DOA
ISICitedReferencesCount 6
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000864518700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-8021
IngestDate Fri Oct 03 12:47:34 EDT 2025
Thu Aug 21 18:39:52 EDT 2025
Thu Sep 04 20:08:42 EDT 2025
Sat Nov 29 06:21:57 EST 2025
Tue Nov 18 21:26:13 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-f5c82d1fd2dedf7c949b58b6147fec64071d5f5774af694ee42f709539c18def3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Ubald Soto, Loma Linda University, United States
Reviewed by: Kenan Sevinç, Koç University, Turkey
This article was submitted to RNA, a section of the journal Frontiers in Genetics
Shrikanth Gadad, Texas Tech University Health Sciences Center El Paso, United States
OpenAccessLink https://doaj.org/article/13669641d3624f59ace5d3297292ad9c
PQID 2723156540
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_13669641d3624f59ace5d3297292ad9c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9530462
proquest_miscellaneous_2723156540
crossref_primary_10_3389_fgene_2022_992444
crossref_citationtrail_10_3389_fgene_2022_992444
PublicationCentury 2000
PublicationDate 2022-09-20
PublicationDateYYYYMMDD 2022-09-20
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-20
  day: 20
PublicationDecade 2020
PublicationTitle Frontiers in genetics
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Yao (B29) 2020; 11
Group (B8) 2005; 365
Hnisz (B10) 2013; 155
Li (B17) 2016; 23
Zhang (B34) 2020; 2020
Duan (B5) 2021; 13
Kim (B12) 2015; 12
Ramírez (B21) 2016; 44
Andrews (B2) 2010
Zhang (B35) 2021; 14
Anders (B1) 2015; 31
Lánczky (B13) 2021; 23
Ham (B9) 2022; 48
Cocce (B3) 2019; 29
Stark (B23) 2011
Loh (B18) 2013; 13
Yu (B31) 2015; 31
Davies (B4) 2013; 381
Swinstead (B25) 2016; 165
Martin (B20) 2011; 17
Sung (B24) 2021; 71
Hurtado (B11) 2011; 43
Garcia-Martinez (B7) 2021; 12
Whyte (B27) 2013; 153
Woo (B28) 2015; 10
Zhang (B33) 2018; 83
Lee (B15) 2020; 17
Yu (B30) 2012; 16
Fu (B6) 2019; 116
Li (B16) 2009; 25
Wang (B26) 2013; 8
Love (B19) 2014; 15
Zhang (B32) 2008; 9
Langmead (B14) 2012; 9
Schmitt (B22) 2016; 29
References_xml – volume: 23
  start-page: e27633
  year: 2021
  ident: B13
  article-title: Web-Based survival analysis tool tailored for medical research (KMplot): Development and implementation
  publication-title: J. Med. Internet Res.
  doi: 10.2196/27633
– volume: 381
  start-page: 805
  year: 2013
  ident: B4
  article-title: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
  publication-title: Lancet
  doi: 10.1016/s0140-6736(12)61963-1
– volume-title: DiffBind differential binding analysis of ChIP-Seq peak data
  year: 2011
  ident: B23
– volume: 2020
  start-page: 1
  year: 2020
  ident: B34
  article-title: Identification and analysis of estrogen receptor α promoting tamoxifen resistance-related lncRNAs
  publication-title: BioMed Res. Int.
  doi: 10.1155/2020/9031723
– volume: 8
  start-page: 2502
  year: 2013
  ident: B26
  article-title: Target analysis by integration of transcriptome and ChIP-seq data with BETA
  publication-title: Nat. Protoc.
  doi: 10.1038/nprot.2013.150
– volume: 153
  start-page: 307
  year: 2013
  ident: B27
  article-title: Master transcription factors and mediator establish super-enhancers at key cell identity genes
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.035
– volume: 48
  start-page: 130
  year: 2022
  ident: B9
  article-title: β-catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine-resistant breast cancer cells
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2022.8341
– volume: 365
  start-page: 1687
  year: 2005
  ident: B8
  article-title: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66544-0
– volume: 17
  start-page: 1550
  year: 2020
  ident: B15
  article-title: Enhancer RNAs in cancer: Regulation, mechanisms and therapeutic potential
  publication-title: RNA Biol.
  doi: 10.1080/15476286.2020.1712895
– volume: 165
  start-page: 593
  year: 2016
  ident: B25
  article-title: Steroid receptors reprogram FoxA1 occupancy through dynamic chromatin transitions
  publication-title: Cell
  doi: 10.1016/j.cell.2016.02.067
– volume: 29
  start-page: 452
  year: 2016
  ident: B22
  article-title: Long noncoding RNAs in cancer pathways
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.03.010
– volume: 17
  start-page: 10
  year: 2011
  ident: B20
  article-title: Cutadapt removes adapter sequences from high-throughput sequencing reads
  publication-title: EMBnet J.
  doi: 10.14806/ej.17.1.200
– volume: 14
  start-page: 4427
  year: 2021
  ident: B35
  article-title: TP53 mutation related and directly regulated lncRNA prognosis markers in hepatocellular carcinoma
  publication-title: Ott
  doi: 10.2147/OTT.S321669
– volume: 12
  start-page: 357
  year: 2015
  ident: B12
  article-title: Hisat: A fast spliced aligner with low memory requirements
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3317
– volume: 44
  start-page: W160
  year: 2016
  ident: B21
  article-title: deepTools2: a next generation web server for deep-sequencing data analysis
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkw257
– volume: 10
  start-page: e0132285
  year: 2015
  ident: B28
  article-title: Inhibition of aerobic glycolysis represses akt/mTOR/HIF-1α Axis and restores tamoxifen sensitivity in antiestrogen-resistant breast cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0132285
– volume: 31
  start-page: 166
  year: 2015
  ident: B1
  article-title: HTSeq-a Python framework to work with high-throughput sequencing data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu638
– volume: 25
  start-page: 2078
  year: 2009
  ident: B16
  article-title: The sequence alignment/map format and SAMtools
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp352
– volume: 16
  start-page: 284
  year: 2012
  ident: B30
  article-title: clusterProfiler: an R package for comparing biological themes among gene clusters
  publication-title: OMICS A J. Integr. Biol.
  doi: 10.1089/omi.2011.0118
– volume: 155
  start-page: 934
  year: 2013
  ident: B10
  article-title: Super-enhancers in the control of cell identity and disease
  publication-title: Cell
  doi: 10.1016/j.cell.2013.09.053
– volume-title: FastQC: A quality control tool for high throughput sequence data
  year: 2010
  ident: B2
– volume: 116
  start-page: 26823
  year: 2019
  ident: B6
  article-title: FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.1911584116
– volume: 13
  start-page: 174
  year: 2013
  ident: B18
  article-title: The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-174
– volume: 12
  start-page: 1786
  year: 2021
  ident: B7
  article-title: Epigenetic mechanisms in breast cancer therapy and resistance
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22024-3
– volume: 11
  start-page: 592912
  year: 2020
  ident: B29
  article-title: Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.592912
– volume: 13
  start-page: 433
  year: 2021
  ident: B5
  article-title: Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells
  publication-title: J. Mol. Cell Biol.
  doi: 10.1093/jmcb/mjab018
– volume: 29
  start-page: 889
  year: 2019
  ident: B3
  article-title: The lineage determining factor GRHL2 collaborates with FOXA1 to establish a targetable pathway in endocrine therapy-resistant breast cancer
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2019.09.032
– volume: 43
  start-page: 27
  year: 2011
  ident: B11
  article-title: FOXA1 is a key determinant of estrogen receptor function and endocrine response
  publication-title: Nat. Genet.
  doi: 10.1038/ng.730
– volume: 15
  start-page: 550
  year: 2014
  ident: B19
  article-title: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
  publication-title: Genome Biol.
  doi: 10.1186/s13059-014-0550-8
– volume: 31
  start-page: 2382
  year: 2015
  ident: B31
  article-title: ChIPseeker: An R/bioconductor package for ChIP peak annotation, comparison and visualization
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btv145
– volume: 9
  start-page: R137
  year: 2008
  ident: B32
  article-title: Model-based analysis of ChIP-seq (MACS)
  publication-title: Genome Biol.
  doi: 10.1186/gb-2008-9-9-r137
– volume: 23
  start-page: 205
  year: 2016
  ident: B17
  article-title: Regulation of lncRNA and its role in cancer metastasis
  publication-title: Oncol. Res.
  doi: 10.3727/096504016x14549667334007
– volume: 71
  start-page: 209
  year: 2021
  ident: B24
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA A Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 9
  start-page: 357
  year: 2012
  ident: B14
  article-title: Fast gapped-read alignment with Bowtie 2
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.1923
– volume: 83
  start-page: 603
  year: 2018
  ident: B33
  article-title: Downregulation of linc00894-002 contributes to tamoxifen resistance by enhancing the TGF-β signaling pathway
  publication-title: Biochem. Mosc.
  doi: 10.1134/s0006297918050139
SSID ssj0000493334
Score 2.3304765
Snippet Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has...
Breast cancer is the leading cause of death in female cancers, and what's worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 992444
SubjectTerms ATP1A1-AS1
breast cancer
FoxA1
Genetics
super enhancer
tamoxifen resistance
Title Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance
URI https://www.proquest.com/docview/2723156540
https://pubmed.ncbi.nlm.nih.gov/PMC9530462
https://doaj.org/article/13669641d3624f59ace5d3297292ad9c
Volume 13
WOSCitedRecordID wos000864518700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-8021
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493334
  issn: 1664-8021
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-8021
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493334
  issn: 1664-8021
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokL4imWR2UkTkihfiWOjwvqwqEsCIG0t8jxQw2iTpVkW3rhzr9mHGerzQUuXHJIHMfxNxl_I0--QehVoYwiuRYZcPk6E1aSrPSSZjUvNfFUelKP6voncr0uNxv1ea_UV8wJS_LAaeKOKC8KVQhqwdMKnyttXG45U0AKmbbKRO9LpNoLpr4n3ss5F2kbE6IwdeQBjyiLydgbBTGHELOFaNTrn5HMeYrk3pqzuofuTmQRL9Mg76MbLjxAt1P5yKuH6Pd7F9ozl1021mE9qYvg1mMgdXj1abOkeIhL0c4xQFddKj3fdlc4pARw3NiUMOR63G_PXYddOI2m0GE9QecsPgnmy3rZ4ybgQZ-1PxvvAnTWR_YJbR-hb6vjr-8-ZFNphcwIwYbM56ZklnrLrLNeGiVUnZc1rNXSOxM396jNfQ7cUPtCCecE8zJK0ylDS-s8f4wOQhvcE4SJ1dpQ6E7yXBiqNPiAItbA4pobT8wCkd08V2bSHY_lL35UEH9EaKoRmipCUyVoFuj19S3nSXTjb43fRvCuG0a97PEEWFE1WVH1LytaoJc76Cv4vuKmiQ6u3fYVk8CAgfUKskByZhOzJ86vhOZ0VOqGCYs__z79H0N8hu7Et465Kow8RwdDt3Uv0C1zMTR9d4huyk15OH4EcPz46_gPVvYPmw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genome-wide+analysis+of+the+FOXA1+transcriptional+regulatory+network+identifies+super+enhancer+associated+LncRNAs+in+tamoxifen+resistance&rft.jtitle=Frontiers+in+genetics&rft.au=Zhang%2C+Xiulei&rft.au=Zhang%2C+Qian&rft.au=Liu%2C+Guangzhi&rft.date=2022-09-20&rft.issn=1664-8021&rft.eissn=1664-8021&rft.volume=13&rft.spage=992444&rft_id=info:doi/10.3389%2Ffgene.2022.992444&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-8021&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-8021&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-8021&client=summon